Key result
The Hancock II bioprosthesis demonstrated 20-year freedom from re-operation of 86.8% in older (≥60 years) and 52.2% in younger (<60 years) aortic valve replacement patients (p<0.0001).
Why the study?
What are the long-term survival and freedom from re-operation rates in patients receiving the Hancock II porcine bioprosthesis?
Population
517 consecutive patients undergoing valve replacement surgery between May 1983 and November 1993. 106…
Design
Cohort
Follow-up
median 12 years (range: 0-25)
Authors
Loading...
Supports age-stratified AVR decisions with Hancock II; leaves open randomized comparisons to newer bioprostheses.
Cohort (n=517)
What are the long-term survival and freedom from re-operation rates in patients receiving the Hancock II porcine bioprosthesis?
The Hancock II porcine bioprosthesis demonstrates excellent long-term durability, with 20-year freedom from re-operation of 79.3% in aortic and 52.8% in mitral positions.
Valfrè et al. (2010) conducted a cohort in Aortic or mitral valve replacement (n=517). Hancock II porcine bioprosthesis was evaluated on Long-term survival and freedom from re-operation. The Hancock II bioprosthesis demonstrated 20-year freedom from re-operation of 86.8% in older (≥60 years) and 52.2% in younger (<60 years) aortic valve replacement patients (p<0.0001).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: